Background: This study was performed to assess angiographic outcomes of newer generation drug-eluting stent [everolimus-(EES) or resolute zotarolimus-eluting stents (R-ZES)] for long or diabetic coronary artery disease. Angiographic efficacy of EES or R-ZES has not been sufficiently evaluated for long or diabetic coronary artery disease. Methods: Patients level data from three randomized trials (Long-DES III, IV and ESSENCE-DIABETES I and II) were pooled to estimate angiographic efficacy of EES or R-ZES. A total of 750 patients underwent EES (n¼373) and R-ZES (n¼377). We evaluated follow-up angiography. Results: Baseline clinical and angiographic characteristics were well balanced. Stent length was similar between two groups (35.2 AE 14.9 mm vs. 35.9 AE 14.4 mm, p¼0.51). Follow-up angiography was done in 546 patients (287 [76.9%] in EES patients and 259 [68.7%] in R-ZES patients). In-stent (2.4% vs. 3.1%, p¼0.64) and insegment restenosis (4.9% vs. 3.9%, p¼0.56) were statistically not different between EES and R-ZES group. In-segment restenosis was similar between EES and R-ZES group in diabetics (3.7% vs. 2.4%, p¼0.51), > 30 mm long stent implantation patients (7.3% vs. 5.8%, p¼0.61), left anterior descending artery disease (3.3% vs. 3.0%, p¼0.86), and 2.5 mm small vessel disease (6.8% vs. 3.5%, p¼0.43). The threshold of stent length for predicting restenosis in overall patients was 37.8 mm (area under the receiver-operating characteristic curve: 0.678, 95% confidence interval: 0.637 to 0.717, p¼0.001), which had a sensitivity and specificity of 70.3% and 61.3%, respectively. Conclusions: EES and R-ZES showed comparable angiographic outcomes in patients at high risk of restenosis and effectively reduced angiographic restenosis across all high risk lesion subsets. The cut-off stent length for predicting angiographic restenosis was 37.8 mm.
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Long-Term Clinical Outcomes of Multiple Overlapping ( ‡60mm) Drug-Eluting Stent Implantation Jung-Min Ahn 1 , Pil Hyung Lee 1 , Jae Hyung Roh 1 , Hyo In Choi 1 , Hanul Choi 2 , Hyun Kuk Kim 1 , Young-Rak Cho 3 , Jong-Young Lee 1 , Won-Jang Kim 1 , Soo-Jin Kang 1 , Duk-Woo Park 1 , Seung-Whan Lee 1 , Young-Hak Kim 3 , Cheol Whan Lee 1 , Seong-Wook Park 1 , Seung-Jung Park 1 1 Asan Medical Center, Seoul, Korea, Republic of, 2 Seoul Asan medical center, Seoul, AK, 3 Asan medical center, Seoul, Korea, Republic of Background: There are limited data regarding the clinical outcomes of very long stent implantations, particularly the use of second generation drug-eluting stents (DES). Methods: From the IRIS-DES Registry, we identified 822 patients who were treated for coronary stenosis using ! 60 mm of overlapping drug-eluting stents. Of these, 269, 137, and 416 patients were treated using cobalt chromium everolimus eluting stent (CoCr-EES), platinum chromium everolimus-eluting stents (PtCr-EES) or sirolimus-eluting stents (SES), respectively. Major adverse cardiac events (MACE) were defined using a composite measure consisting of death, myocardial infarction (MI; periprocedural or spontaneous), or target vessel revascularization (TVR). Results: Per target lesion, the average stent number was 2.7 AE 0.7 and the average stent length was 76.3 AE 14.8 mm. On 2-year clinical follow-up, the rate of MACE, death, spontaneous MI, TVR, and stent thrombosis (definite or probable stent thrombosis) were 21.7%, 4.2%, 1.9%, 7.7%, and 0.7%, respectively. Although 139 patients (16.9%) suffered from periprocedural MI, this was not independently associated with death, spontaneous MI, or TVR (hazard ratio [HR], 1.29; 95% confidence interval [CI] 0.57-2.95, p ¼ 0.54). In addition, there were no statistical differences between EES and SES implantation in terms of the adjusted risks of MACE (HR, 1.32; 95% CI 0.90-1.94, p ¼ 0.16). Conclusions: When treating diffuse coronary stenosis, multiple overlapping stent implantations using second generation DES appear to be equally safe and effective. Although periprocedural MI frequently occurred, it was not associated with an increase in long-term adverse clinical outcomes.
TCT-209
Very-long term (11 years) follow up of a single center, complex cohort of patients treated exclusively with drug-eluting stents Background: Despite the extensive knowledge accrued on DES in the past years, there is still lack of consistent data on the very late outcomes of these devices, especially after 5 years of their implantation. We sought to provide the longest clinical follow-up data on outcomes of unselected patients treated solely with DES. Methods: The DESIRE registry is a prospective, single-center registry encompassing all consecutive patients treated solely with DES since May 2002. The primary goal is the very long-term occurrence of MACE and stent thrombosis (ST). Patients were clinically followed at 1, 6 and 12 months and then annually. Results: A total of 4,790 patients were included. The mean age was 64 AE 11 years. DM was detected in 29.7% and 44.8% presented with acute coronary syndrome. Follow-up was obtained in 98.5% of the patients (median 5.6 years). Currently, 79.6% of the population is free of any MACE. TVR was performed in 5.3% of the patients. Q-wave MI rate was only 1.7% while total ST rate was 1.9%. The majority of definite ST cases occurred between the 1st and 3rd years. Independent predictors of MACE were treatment of SVG (HR 1,63; 95% CI, 1.22 to 2.18, p¼ 0.001), multivessel disease (HR 1.39; 95% CI, 1.03 to 1.87, p<0.001), residual stenosis (HR 1.3; 95% CI, 1.1 to 1.5, p¼ 0.034), DM (HR 1.6; 95% CI, 1.1 to 2.2, p¼ 0.006) and renal insufficiency (HR 1.5; 95% CI, 1.34 to 1.81, p¼ 0.004). Independent predictors of ST were PCI for STEMI (HR 3.5; 95% CI, 1.3 to 9.4, p¼ 0.013), stent length (HR 1.8; 95% CI, 1.09 to 3.02, p¼0.023), moderate/severe calcification at lesion site (HR 2.38; 95% CI, 1.34 to 4.23, p¼0.003), and in-stent residual stenosis (HR 1.04; 95% CI, 1.01 to 1.06, p¼0.003). Conclusions: The DESIRE registry probably represents the longest FU of a real world cohort treated solely with DES. In our single center experience, the use of DES was associated with very long-term safety and effectiveness with acceptable low rates of adverse clinical events, including ST. Also, there was no steady annual increment in the occurrence of ST, with a marked decrease of this complication after the 3rd year of FU. Background: Diabetes mellitus remains a significant predictor of adverse clinical outcomes after percutaneous coronary intervention (PCI). Outcomes after 2nd generation drug-eluting stent (DES) implantation in diabetics remains ill-defined. Aim of this study was to compare the clinical outcomes of the Resolute Zotarolimus-eluting stent (R-ZES) in diabetic and non-diabetic patients. Methods: From August 2008 to November 2010, patients with significant coronary artery stenosis suitable for PCI and successful implantation of at least one R-ZES were included in a multicenter, prospective Italian database. Primary end-point of the study was to assess the incidence of a composite of cardiac death, target lesion revascularization (TLR) and myocardial infarction (MI) between diabetic and non-diabetic patients and among diabetics between insulin (ITDM) and non insulin-treated (NITDM). Results: During the study period 1,216 patients (365 diabetics and 851 nondiabetics)suitable for PCI were enrolled. Acute coronary syndromes were the reason for revascularization in 549 (45.1%) patients (diabetics: 171, 46.8% vs. non-diabetics: 378, 44.4%; p 0.22). Multi-vessel PCI was performed in 211 (17.4%) patients (diabetics: 66; 18.1% vs. non-diabetics: 145; 17.0%, p¼0.6). As compared with non-diabetics, diabetics were older (67.2AE10.5 vs. 64.8AE11.0, p<0.001), more often female (25.5% vs. 18.4, p¼0.05) or hypertensive (87.3 vs. 72.3, p<0.001) www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM-5:30 PM 
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